Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00123201
Other study ID # S175.2.103
Secondary ID
Status Completed
Phase Phase 2
First received July 21, 2005
Last updated January 15, 2015
Start date September 2005
Est. completion date March 2007

Study information

Verified date September 2006
Source Solvay Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the efficacy and safety of dronabinol MDI for the acute treatment of moderate to severe migraine headache.


Recruitment information / eligibility

Status Completed
Enrollment 0
Est. completion date March 2007
Est. primary completion date March 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Male or female subjects 18 to 65 years, inclusive, with clinically diagnosed migraine with or without aura based on International Headache Society criteria

Exclusion Criteria:

- Subjects who experience migraine with prolonged aura; familiar hemiplegic migraine; migrainous infarction or basilar migraine; and those with greater than eight migraine attacks per month and/or greater than 14 migraine days per month.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Intervention

Drug:
Dronabinol MDI


Locations

Country Name City State
United States Site 21 Alexandria Virginia
United States Site 3 Anaheim California
United States Site 25 Atlanta Georgia
United States Site 2 Boston Massachusetts
United States Site 16 Bryan Texas
United States Site 1 Chicago Illinois
United States Site 12 Chicago Illinois
United States Site 29 Clementon New Jersey
United States Site 17 Colleyville Texas
United States Site 23 Fargo North Dakota
United States Site 10 Huntsville Alabama
United States Site 8 Huntsville Alabama
United States Site 28 Lexington Kentucky
United States Site 20 Madisonville Kentucky
United States Site 26 Melbourne Florida
United States Site 4 Mt. Vernon New York
United States Site 22 New Port Richey Florida
United States Site 19 Omaha Nebraska
United States Site 18 Orange City Florida
United States Site 27 Pembroke Pines Florida
United States Site 14 Plantation Florida
United States Site 24 Plantation Florida
United States Site 13 Portland Oregon
United States Site 9 Raleigh North Carolina
United States Site 6 San Fransisco California
United States Site 5 Spartanburg South Carolina
United States Site 7 St. Petersburg Florida
United States Site 15 Stockton California
United States Site 11 Tucson Arizona

Sponsors (2)

Lead Sponsor Collaborator
Solvay Pharmaceuticals Nektar Therapeutics

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Recruiting NCT02202486 - Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI N/A
Completed NCT01687660 - Acupuncture for Migraine Prophylaxis N/A
Completed NCT00363532 - Functional MRI (fMRI) in CGRP Induced Migraine N/A
Completed NCT04406649 - A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine Phase 3
Completed NCT03874832 - A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects Phase 1
Recruiting NCT05565001 - The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. N/A
Completed NCT04533568 - Ibuprofen in Migraine Patients Phase 4
Recruiting NCT06459635 - Migraine Attack Pain Phase Prediction Study
Recruiting NCT05416476 - Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine Phase 3
Completed NCT04636359 - Study the Effect of Acupuncture on Migraine Patient Without Aura Via Functional Magnetic Resonance Imaging. N/A
Completed NCT00534560 - Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache Phase 2
Terminated NCT04936061 - Transnasal Cooling for Migraine N/A
Recruiting NCT05281770 - Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
Completed NCT00380263 - PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow N/A
Completed NCT00334178 - Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine Phase 3
Recruiting NCT06051604 - Mi-Helper Transnasal Cooling for Acute Treatment of Migraine N/A
Recruiting NCT06414044 - Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients
Completed NCT03472378 - Can DFN-15 Terminate Migraine With Allodynia? Phase 2
Recruiting NCT05211154 - Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine Phase 4
Recruiting NCT04157192 - Brain Connectome for Acupuncture-treated Migraine Patients N/A